162 related items for PubMed ID: 8979286
21. Growth curves for congenital adrenal hyperplasia from a national retrospective cohort.
Bretones P, Riche B, Pichot E, David M, Roy P, Tardy V, Kassai B, Gaillard S, Bernoux D, Morel Y, Chatelain P, Nicolino M, Cornu C, French Collaborative CAH Growth Study Group.
J Pediatr Endocrinol Metab; 2016 Dec 01; 29(12):1379-1388. PubMed ID: 27852974
[Abstract] [Full Text] [Related]
22. Obesity among children and adolescents with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
Völkl TM, Simm D, Beier C, Dörr HG.
Pediatrics; 2006 Jan 01; 117(1):e98-105. PubMed ID: 16396852
[Abstract] [Full Text] [Related]
23. HYDROCORTISONE THERAPY AND GROWTH TRAJECTORY IN CHILDREN WITH CLASSICAL CONGENITAL ADRENAL HYPERPLASIA.
Bizzarri C, Improda N, Maggioli C, Capalbo D, Roma S, Porzio O, Salerno M, Cappa M.
Endocr Pract; 2017 May 01; 23(5):546-556. PubMed ID: 28225306
[Abstract] [Full Text] [Related]
24. A Retrospective Analysis of the Growth Pattern in Patients with Salt-wasting 21-Hydroxylase Deficiency.
Kawano A, Kohno H, Miyako K.
Clin Pediatr Endocrinol; 2014 Apr 01; 23(2):27-34. PubMed ID: 24790384
[Abstract] [Full Text] [Related]
25. Final height in congenital adrenal hyperplasia: the dilemma of hypercortisolism versus hyperandrogenism.
Cordeiro GV, Silva IN, Goulart EM, Chagas AJ, Kater CE.
Arq Bras Endocrinol Metabol; 2013 Mar 01; 57(2):126-31. PubMed ID: 23525290
[Abstract] [Full Text] [Related]
26. Experience with long-term glucocorticoid treatment in congenital adrenal hyperplasia: growth pattern compared with genetic height potential.
Aycan Z, Ocal G, Berberoglu M, Cetinkaya E, Adiyaman P, Evliyaoglu O.
J Pediatr Endocrinol Metab; 2006 Mar 01; 19(3):245-51. PubMed ID: 16607925
[Abstract] [Full Text] [Related]
27. Initial high dose hydrocortisone (HDC) treatment for 21-hydroxylase deficiency (21-OHD) does not affect linear growth during the first three years of life.
Takasawa K, Ono M, Miyai K, Matsubara Y, Takizawa F, Onishi T, Kashimada K, Mizutani S.
Endocr J; 2012 Mar 01; 59(11):1001-6. PubMed ID: 22785554
[Abstract] [Full Text] [Related]
28. Normalization of height and excess body fat in children with salt-wasting 21-hydroxylase deficiency.
Mendes-Dos-Santos CT, Lemos-Marini SH, Baptista MT, Guerra-Junior G, De-Mello MP, Paulino MF, Morcillo AM.
J Pediatr (Rio J); 2012 Mar 01; 87(3):263-8. PubMed ID: 21660369
[Abstract] [Full Text] [Related]
29. Growth pattern and final height in 21-hydroxylase deficiency.
Bajpai A, Pandey RM, Kabra M, Menon PS.
Indian Pediatr; 2007 Oct 01; 44(10):771-3. PubMed ID: 17998577
[Abstract] [Full Text] [Related]
30. Near-final height in 82 Chinese patients with congenital adrenal hyperplasia due to classic 21-hydroxylase deficiency: a single-center study from China.
Juan L, Huamei M, Zhe S, Yanhong L, Hongshan C, Qiuli C, Jun Z, Song G, Minlian D.
J Pediatr Endocrinol Metab; 2016 Jul 01; 29(7):841-8. PubMed ID: 27054598
[Abstract] [Full Text] [Related]
31. Gender related differences in glucocorticoid therapy and growth outcomes among pubertal children with 21-hydroxylase deficiency congenital adrenal hyperplasia (CAH).
Deslauriers JR, Lenz AM, Root AW, Diamond FB, Bercu BB.
J Pediatr Endocrinol Metab; 2012 Jul 01; 25(9-10):977-81. PubMed ID: 23426829
[Abstract] [Full Text] [Related]
32. Growth analysis in patients with 21-hydroxylase deficiency influence of glucocorticoid dosage, age at diagnosis, phenotype and genotype on growth and height outcome.
Grigorescu-Sido A, Bettendorf M, Schulze E, Duncea I, Heinrich U.
Horm Res; 2003 Jul 01; 60(2):84-90. PubMed ID: 12876419
[Abstract] [Full Text] [Related]
33. Monitoring treatment in congenital adrenal hyperplasia.
Appan S, Hindmarsh PC, Brook CG.
Arch Dis Child; 1989 Sep 01; 64(9):1235-9. PubMed ID: 2640553
[Abstract] [Full Text] [Related]
34. Effect of the dose of oral hydrocortisone on growth rate during long-term treatment of children with salt losing congenital adrenal hyperplasia.
Ciaccio M, Montiveros C, Rivarola MA, Belgorosky A.
Medicina (B Aires); 2002 Sep 01; 62(6):551-4. PubMed ID: 12532689
[Abstract] [Full Text] [Related]
35. Growth patterns and outcomes in congenital adrenal hyperplasia; effect of chronic treatment regimens.
Rasat R, Espiner EA, Abbott GD.
N Z Med J; 1995 Aug 11; 108(1005):311-4. PubMed ID: 7644165
[Abstract] [Full Text] [Related]
36. Characteristics of Growth in Children With Classic Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency During Adrenarche and Beyond.
Troger T, Sommer G, Lang-Muritano M, Konrad D, Kuhlmann B, Zumsteg U, Flück CE.
J Clin Endocrinol Metab; 2022 Jan 18; 107(2):e487-e499. PubMed ID: 34599587
[Abstract] [Full Text] [Related]
37. Growth inhibition by glucocorticoid treatment in salt wasting 21-hydroxylase deficiency: in early infancy and (pre)puberty.
Stikkelbroeck NM, Van't Hof-Grootenboer BA, Hermus AR, Otten BJ, Van't Hof MA.
J Clin Endocrinol Metab; 2003 Aug 18; 88(8):3525-30. PubMed ID: 12915631
[Abstract] [Full Text] [Related]
38. The urinary steroidome of treated children with classic 21-hydroxylase deficiency.
Kamrath C, Wettstaedt L, Boettcher C, Hartmann MF, Wudy SA.
J Steroid Biochem Mol Biol; 2017 Jan 18; 165(Pt B):396-406. PubMed ID: 27544322
[Abstract] [Full Text] [Related]
39. [Comparative study of prednisolone versus hydrocortisone acetate for treatment of patients with the classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency].
Leite FM, Longui CA, Kochi C, Faria CD, Borghi M, Calliari LE, Monte O.
Arq Bras Endocrinol Metabol; 2008 Feb 18; 52(1):101-8. PubMed ID: 18345402
[Abstract] [Full Text] [Related]
40. Growth and pubertal development in patients with congenital adrenal hyperplasia due to 11-beta-hydroxylase deficiency.
Hochberg Z, Schechter J, Benderly A, Leiberman E, Rosler A.
Am J Dis Child; 1985 Aug 18; 139(8):771-6. PubMed ID: 3875277
[Abstract] [Full Text] [Related]
Page: [Previous] [Next] [New Search]
